- 1 <u>Title</u>: The Impact of Social Determinants of Health and Lifestyle on the Association of Lipoprotein(a)
- 2 with Myocardial Infarction and Stroke
- 3
- 4 <u>Authors</u>: Eric J. Brandt MD, MHS^{1,2;}; Matthias Kirch, MS¹; Nimai Patel, MD³; Chaitanya Chennareddy,
- 5 BS⁴; Venkatesh L. Murthy, MD, PhD^{2,5}; Sascha N. Goonewardena, MD, PhD²
- 6
- 7 <u>Affiliations</u>
- 8 ¹ Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI
- 9 ² Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann
- 10 Arbor, MI
- ³ Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health
- 12 Science Center at Houston, Houston, TX
- 13 ⁴Case Western Reserve University School of Medicine, Cleveland, OH
- ⁵ Divisions of Nuclear Medicine and Cardiothoracic Imaging, Department of Radiology, University of
- 15 Michigan, Ann Arbor, MI
- 16
- 17 Corresponding Author and Reprint Contact
- 18 Eric J Brandt, MD, MHS
- 19 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106, USA
- 20 Telephone: +1 586 215 4404; Fax: n/a
- 21 Email: EricJBrandtMD@gmail.com
- 22 Twitter: @DrEJBMD
- 23
- 24 <u>Word count (text)</u>: 3096
- 25 <u>Word count (abstract)</u>: 315

26 Abstract

27 Background: In European cohorts, a higher Mediterranean diet or Life's Simple 7 (LS7) score abolished 28 or attenuated the risk associated with increasing Lipoprotein(a) [Lp(a)] on cardiovascular outcomes. This 29 is unstudied in US cohorts. The impact of social determinants of health (SDOH) on the association of 30 Lp(a) with cardiovascular outcomes remains unstudied. We sought to test if a SDOH score and LS7 score 31 impacts the association of Lp(a) with myocardial infarction (MI) or stroke. 32 Methods: Observational Cohort of US Adults from the Atherosclerosis Risk in Communities (ARIC) and 33 Multi-Ethnic Study of Atherosclerosis (MESA) cohorts. We performed sequential multivariable Cox 34 proportional hazard analysis, first adjusting for age, gender, non-HDL-C, race and ethnicity, then added 35 SDOH and LS7 scores sequentially. The primary outcomes were time until first fatal or nonfatal MI or 36 stroke. 37 Results: ARIC (n=15,072; median Lp(a)=17.3 mg/dL) had 16.2 years average follow up. MESA 38 (n=6,822; median Lp(a)=18.3 mg/dL had 12.3 years average follow-up. In multivariable analyses 39 adjusted for age, gender, race and ethnicity, and non-HDL-C, Lp(a) was associated (HR, p-value) with MI 40 in ARIC (1.10, <0.001) and MESA (1.09, <0.001), and stroke in ARIC (1.08, <0.001) but not MESA 41 (0.97, 0.50). With SDOH and LS7 added to the model associations remained similar (association of Lp(a) 42 with MI in ARIC 1.09, <0.001 and in MESA 1.10, 0.001, with stroke in ARIC 1.06, <0.003 and in MESA 43 0.96, 0.39). In models with all covariates, each additional SDOH correlated positively with MI (ARIC 44 1.13, <0.001; MESA 1.11, <0.001) and stroke (ARIC 1.17, <0.001; HR 1.07, p=0.11) and each additional 45 LS7 score point correlated negatively with MI (ARIC 0.81, <0.001; MESA 0.84, <0.001) and stroke 46 (ARIC 0.82, <0.001; MESA 0.84, <0.001). 47 Conclusions and Relevance: SDOH and lifestyle factors were predictors for MI and stroke that did not 48 impact the association between Lp(a) and cardiovascular events. Our findings support that Lp(a) is an

49 independent risk factor for MI and possibly stroke.

50 Keywords: Lipoprotein(a), lifestyle, social determinants of health, acute myocardial infarction, stroke

51 <u>Introduction</u>

Lipoprotein(a) (Lp(a)) is an independent risk factor for the development of atherosclerotic 52 cardiovascular diseases (ASCVD).¹ Aside from apheresis, there are no clinically available therapies that 53 54 specifically target lowering of Lp(a), although agents are being developed (e.g., pelacarsen, olpasiran, 55 etc.) and other FDA-approved therapies (e.g., PCSK9 inhibitors and Niacin) have small impacts on Lp(a) 56 levels. While awaiting therapeutic agents, patients with elevated Lp(a) can lower their risk for ASCVD with statins and other lipids lowering therapies.¹ Additionally, lifestyle and social determinants of health 57 58 (SDOH) have large impacts on cardiovascular outcomes and can be targets for risk modification.^{2,3} 59 Findings from two European cohorts suggest that a healthy lifestyle can decrease the risk for 60 ASCVD among those with elevated Lp(a). In the EPIC-Norfolk cohort (n=14,051 men and women from 61 Norfolk, UK), those in the top versus the bottom tertile of Life's Simple 7 (LS7) score and Lp(a) > 5062 mg/dL had a hazard ratio (HR) of 0.33 (95% CI, 0.17-0.63) for death from coronary heart disease or stroke.⁴ The risk of elevated Lp(a) was not completely abolished since those with Lp(a) < 50 mg/dL in the 63 64 top tertile of LS7 score had a HR of 0.17 (95% CI 0.12-0.31). Second, in the ATTICA study (n=3,042 65 Greek men and women) without ASCVD, a higher Mediterranean diet score did not influence Lp(a) 66 levels, but did abolish (HR 1.00, 95%CI 0.98-1.01) the risk associated with Lp(a) for having an ASCVD event.5 67 SDOH are the conditions in which people are born, live, and work.⁶ SDOH are associated with 68 69 ASCVD events and may help to explain the differences in cardiovascular risk between different populations.^{7–9} SDOH can impact risk for ASCVD via psychological, behavioral, and biologic 70 mechanisms, which include chronic stress responses and systemic inflammation.¹⁰ Given that Lp(a) is an 71 72 acute phase reactant whose level is mediated by periods of inflammation, it is plausible that SDOH could 73 impact the association of Lp(a) on risk for CVD events.¹¹ 74 The impact of lifestyle factors on the association of Lp(a) with cardiovascular events has not been 75 tested in US cohorts. Further, the impact of SDOH on the association of Lp(a) with cardiovascular 76 outcomes is untested in any cohorts. We hypothesized that accounting for SDOH and lifestyle factors

would greatly mitigate the risk associated with Lp(a) for myocardial infarction (MI) or stroke in UScohorts.

79 Methods

80 *Data*

81 We performed retrospective analysis of prospectively data from the Atherosclerosis Risk in 82 Communities (ARIC) and the Multi-Ethnic Study of Atherosclerosis (MESA) cohorts. ARIC and MESA 83 are prospective, longitudinal investigations into the cardiac risk factors, health outcomes, and 84 demographic patterning of atherosclerosis. ARIC enrolled men and women aged 35-84 years, beginning 85 in 1987 from four US communities. MESA enrolled men and women aged 45-64 years, beginning in 86 2000 from six US communities. Data were obtained via requests to the National Institute of Health's 87 Biologic Specimen and Data Repository Information Coordinating Center. We used data from the first 88 examination cycle and cohort surveillance data for cardiovascular events. The study was deemed exempt 89 from review by the University of Michigan institutional review board. 90 **Outcomes**

91 The primary outcomes were time until first fatal or nonfatal MI or stroke. In ARIC, outcomes
92 were tracked semi-annually through 2006. In MESA, outcomes were tracked annually through 2015.

93 Lipoprotein(a) assays

94 In ARIC, Lp(a) was measured as protein mass using a double-antibody enzyme-linked 95 immunosorbent assay technique.^{12,13} The protein-mass represents about one-third of the total molecule 96 mass,¹⁴ thus the Lp(a)-mass measured in ARIC Visit 1 was tripled to be similar to the Lp(a) total-mass 97 measurement in MESA. This technique, although isoform sensitive, had excellent correlation (r=0.88) 98 with samples performed at Visit 4 using an isoform insensitive turbidimetric immunoassay (Denka Seiken 99 Co. Ltd., Tokyo, Japan).¹⁵ In MESA, Lp(a) was measured from cold storage 10-11 years after sample 100 collection as mass content using an isoform insensitive latex-enhanced turbidimetric immunoassay (Denka Seiken, Tokyo, Japan) by Health Diagnostics Laboratory (Richmond, Virginia).^{16,17} 101

102 Statistical Design and Analysis

103	We performed sequential multivariable cox proportional hazard analysis. In Model 1, covariates
104	were age, gender, race and ethnicity, non-HDL-C (per 25 mg/dL increase), and Lp(a) (per 25 mg/dL
105	increase). Model 2 included a SDOH score: an integer score ranging from zero to five in ARIC and zero
106	to 11 in MESA. SDOH in ARIC included being unemployed, income <300% of the federal poverty level,
107	<high access,="" and="" education,="" for="" government="" health="" healthcare="" insurance.<="" no="" or="" regular="" school="" site="" td=""></high>
108	SDOH in MESA included these determinants and not being married or living with a partner, not owning a
109	home, reports of loneliness/lack of social support, unsafe neighborhood residence, experience of
110	discrimination in the last year, and somewhat or very serious food access problems. Model 3 included the
111	LS7 score (smoking status, body mass index, physical activity, dietary score, total cholesterol, blood
112	pressure, and fasting plasma glucose), which has been previously defined. ³ Each category received zero to
113	two points (range 0-14). Non-HDL-C was calculated by subtracting HDL-C from Total Cholesterol and
114	corrected for Lp(a) mass (non-HDL-C=Total Cholesterol-HDL-C-(Lp(a)x0.3)). ¹⁸ We used interaction
115	terms to test whether Lp(a) is moderated by SDOH or LS7 scores.
116	To test the proportional hazards assumption we examined log-log plots of survival for parallel
117	curves in all fully constructed models, which were acceptable for all outcomes. All p-values were two-
118	sided. Statistical significance was set at p<0.05. Data were analyzed using Stata software, version 16
119	(StataCorp, LLC).
120	Sensitivity analyses
121	To understand if correlations between SDOH and LS7 scores could impact outcomes, we tested
122	whether SDOH or LS7 scores predicted Lp(a) level in age, gender, race and ethnicity, and non-HDL-C
123	adjusted models.
124	To understand the association between categorical Lp(a) level and cardiovascular outcomes we
125	use coarsened exact matching to match cases (Lp(a) >50 mg/dL) to controls (Lp(a) <50 mg/dL). In ARIC,
126	matching covariates were coarsened to age (44-55, or 56-66), non-HDL-C (0-120.0, 120.1-160.0, 160.1-
127	200.0, 200.1-240.0, and ≥240.1 mg/dL), SDOH score (0, 1-2, 3-5), and LS7 score (0-4, 5-9, 10-14). Non-

- 128 coarsened variables included gender and race and ethnicity. In MESA matching covariates were similar
- except age (44-57, 57-70, and 70-84) and SDOH score (0-1, 1-3, 3-5, >5). We repeated cox proportional
- 130 hazards regression in the same three models as described above except that we consider Lp(a) as a three-
- 131 level outcome ($\leq 50 \text{ mg/dL}$, $\geq 50 \text{ to } \leq 100 \text{ mg/dL}$, and $\geq 100 \text{ mg/dL}$).
- 132 <u>Results</u>
- **133** *Population Characteristics*
- 134 In ARIC the mean age was 54 years and in MESA 62 years. Most were female (54.5% in ARIC
- and 52.9% in MESA, Table 1). The largest race and ethnicity represented was non-Hispanic White
- 136 (73.9% in ARIC, 38.5% in MESA), followed by non-Hispanic Black (26.1% in ARIC, 27.8% in MESA),
- 137 and only MESA included Chinese (11.8%) and Hispanic (22.0%) individuals. Mean Lp(a) was similar in
- both cohorts (30.3 mg/dL in ARIC and 30.1 mg/dL in MESA), whereas non-HDL-C was higher in ARIC
- 139 (155 mg/dL) than MESA (134 mg/dL). SDOH scores were lower in ARIC (mean(SD)=1.0(1.1)) than
- 140 MESA (mean=2.3(1.7)). Mean(SD) LS7 score was similar in ARIC (7.8(2.3)) and MESA (8.3(2.1)).
- 141 *Lp(a) association with SDOH and LS7 scores*
- 142 In age, gender, and race and ethnicity adjusted models, SDOH score did not predict Lp(a) level
- 143 (increase in mg/dL Lp(a) per SDOH), 95% CI) in either ARIC (0.50 (-0.003, 1.00)) or MESA (0.24 (-
- 144 0.27, 0.74)). However, LS7 score did predict lower Lp(a) level in both ARIC (-0.68 (-0.90, -0.45) and
- 145 MESA (-0.46, (-0.85, -0.07)).
- 146 Myocardial Infarction
- 147 In all models, Lp(a) (per 25 mg/dL increase) was associated with MI (**Table 2**). The HR (95%
- 148 CI) only slightly attenuated after adding SDOH and LS7 into the models (in ARIC from 1.11 (1.08, 1.14)
- to 1.09 (1.06, 11) and in MESA from 1.11 (1.05, 1.17) to 1.10 (1.04, 1.16)). The association between non-
- 150 HDL-C and MI in ARIC (1.16 (1.14, 1.18)) and MESA (1.09 (1.03, 1.05)) was similar when adding
- 151 SDOH (1.15 (1.13, 1.17) in ARIC and 1.09 (1.03, 1.15) in MESA), then attenuated substantially once
- 152 LS7 score was added in ARIC (1.04 (1.02, 1.06) and nonsignificant in MESA (1.02 (0.96, 1.08)).

153	Among demographic characteristics, there was no change in the association between age and MI
154	and only a small change in association between gender and MI when adding SDOH and LS7 score (Table
155	2). There were changes in the association between race and ethnicity and MI when adding SDOH and
156	LS7 into the models; the association of identifying as non-Hispanic Black compared to non-Hispanic
157	White changed in ARIC from 1.34 (1.24, 1.45) to 0.88 (0.80, 0.96) and in MESA from 0.95 (0.78, 1.17)
158	to 0.72 (0.58, 0.89). For those in MESA identifying as Hispanic, the association shifted from 1.01 (0.82,
159	1.24) to 0.75 (0.59, 0.94). There was no significant shift for those identifying as non-Hispanic Chinese.
160	Given the large changes in association we also tested for interactions between race and ethnicity with
161	SDOH and LS7 scores, all of which were nonsignificant (p>0.05).
162	There were no significant interactions between SDOH and Lp(a) on MI in ARIC (HR 1.01,
163	p=0.46) or MESA (1.01, p=0.68). There was an interaction with a small effect size between LS7 and
164	Lp(a) on MI in MESA (0.97, p=0.03), but not ARIC (1.00, p=0.58).
165	Stroke
166	Lp(a) associated with stroke in ARIC, but not in MESA (Table 3). In ARIC, the association with
167	stroke (HR (95% CI)) only slightly declined from 1.08 (1.05, 1.12) to 1.06 (1.02, 1.09) when including
168	SDOH and LS7 scores. The association between non-HDL-C and stroke in ARIC (1.09 (1.06, 1.11)) and
169	MESA (1.10 (1.01, 1.19) decreased slightly when adding SDOH (1.08 (1.05, 1.11) in ARIC and 1.10
170	(1.02, 1.19) in MESA)), then became non-significant once LS7 score was added (0.98 (0.95, 1.01) in
171	ARIC and 1.03 (0.94, 1.12) in MESA).
172	Among demographic characteristics, there was no change in association between age and stroke
173	and only a slight shift between gender and stroke when adding SDOH and LS7 score to the models
174	(Table 3). Again there were shifts in associations for race and ethnicity and stroke; identifying as non-
175	Hispanic Black compared to non-Hispanic White changed when adding SDOH and LS7 scores to the

176 models in ARIC from HR 1.96 (1.77, 2.18) to 1.24 (1.10, 1.40) and in MESA from 1.43 (1.06, 1.95) to

177 1.12 (0.82, 1.54). For those in MESA identifying as Hispanic, the association also shifted from 1.53 (1.14,

178 2.06) to 1.20 (0.87, 1.66). There was no significant shift for those identifying as non-Hispanic Chinese.

179 Given the large changes in association we also tested for interactions between race and ethnicity with

- 180 SDOH and LS7 scores, all of which were nonsignificant (p>0.05).
- 181 There were no significant interactions between SDOH and Lp(a) on stroke in ARIC (HR 1.01,
- 182 p=0.38) or MESA (1.01, 0.67) nor between LS7 and Lp(a) on stroke in ARIC (0.99, 0.40) or MESA

183 (0.98, 0.36).

- 184 *Coarsened Exact Matching*
- 185 In ARIC, there were 214 (1.9% of those with Lp(a) <50 mg/dL) individuals unmatched with
- 186 Lp(a) <50 mg/dL and 535 (14.8%) with $Lp(a) \ge 50 \text{ mg/dL}$. In MESA, there were 1004 (18.7%)
- 187 individuals unmatched with Lp(a) <50 mg/dL and 146 (10.0%) with Lp(a) >50 mg/dL. In ARIC, weight
- 188 cases were similar to weighted controls in all factors except for Lp(a) (81.3 mg/dL vs 19.4 mg/dL,

189 p<0.001) (Table 4). In MESA, cases were similar to controls except for non-HDL-C (122.7 mg/dL vs

190 125.8 mg/dL, p=0.005) and Lp(a) (86.0 mg/dL vs 18.8 mg/dL, p<0.001).

- 191 In fully adjusted models that included SDOH score and LS7 score, $Lp(a) \ge 50 \text{ mg/dL}$ to <100
- 192 mg/dL was associated with MI in ARIC (HR 1.13,p < 0.001) and MESA (1.12, 0.12) (Figure 1). Lp(a)

193 \geq 100 mg/dL was also associated with MI in ARIC (1.44, p<0.001) and MESA (1.57, 0.007). Associations

between other covariates and MI were similar, including similar shifts in association between race and

ethnicity with MI after adding SDOH and LS7 scores to the model (**Table 5**).

- 196 In fully adjusted models that included SDOH score and LS7 score, Lp(a) >50 mg/dL to <100
- 197 mg/dL was associated with stroke in ARIC (1.17, 0.01), but not in MESA (1.18, 0.31) (Figure 1). Lp(a)
- 198 > 100 mg/dL was also associated with stroke in ARIC (1.26, 0.02), but not in MESA (0.77, 0.43).

199 Associations between other covariates and MI were similar, including similar shifts in association

between race and ethnicity with stroke after adding SDOH and LS7 scores to the model (Table 6).

201 <u>Discussion</u>

In this observational study of two well-characterized, multi-center US cohorts, Lp(a) was associated with MI in both cohorts and stroke in ARIC but not MESA. Accounting for SDOH and lifestyle factors did not attenuate the association between Lp(a) and MI or stroke. However, lifestyle

factors and SDOH were strong predictors of MI or stroke. The large impact of adding SDOH and LS7
scores on the association between race and ethnicity and non-HDL-C with cardiovascular events suggests
that SDOH and LS7 may mediate these associations.

Based on the results of two prior studies,^{4,5} we expected that social and lifestyle factors would 208 209 mediate the risk for ASCVD events related to Lp(a). However, this was not the case since the risk 210 associated with Lp(a) on MI and stroke did not change when accounting for LS7 or SDOH scores. This 211 differed from the ATTICA study since the addition of a Mediterranean diet score led to an abolishment of 212 the risk from Lp(a). This was more similar to the EPIC-Norfolk study wherein despite better lifestyle 213 associated with lower risk but did not abolish the risk among those with elevated Lp(a). Social and 214 lifestyle factors also unlikely moderate the effect of Lp(a) on outcomes since interaction terms were not 215 sufficiently compelling. This was similar to EPIC-Norfolk since interaction tests were also insignificant 216 in this cohort,⁴ but differed from ATTICA wherein an interaction between Mediterranean diet score and 217 Lp(a) was significant (p<0.001).⁵

218 Lp(a) is an acute phase reactant that may increase in times of inflammation. The chronic stressors from SDOH could have been expected to impact Lp(a) levels.¹¹ However, we did not observe that SDOH 219 220 score correlated with Lp(a) levels. There was however an observed, albeit small impact of LS7 score on 221 Lp(a) levels, which is likely not clinically relevant. This could be because LS7 points are given for lower 222 cholesterol levels, thus there could be collinearity (although post-hoc testing (not shown) did not reveal 223 high collinearity between LS7 or non-HDL-C and Lp(a)). Also, bariatric surgery or lower BMI has correlated in some studies with lower Lp(a) level,^{19,20} although this observation is inconsistent.^{21,22} Lastly, 224 increased healthy lifestyle may could have anti-inflammatory impacts that could impact Lp(a) level.²³ 225 226 Even after accounting for many factors, Lp(a) remained associated with MI. This was observed 227 when tested as a linear association and again after matching cases to controls based on Lp(a) as a 228 categorical variable. Our matching analysis achieved excellent balance between cases and controls, with

the only unbalanced factors as non-HDL-C, which differed by 3 mg/dL and we do not expect to account

230 for a large difference in associated outcomes. In this matching analysis our results were consistent with

prior studies, 1 Lp(a) >50 mg/dL had a moderate effect size on risk for MI, which was higher at levels 231 232 \geq 100 mg/dL. This was similar between cohorts. In a meta-analysis of studies, an Lp(a) of 48 mg/dL had a HR of about 1.1-1.2 and a level of 96 mg/dL or above a HR of about 1.3.²⁴ Increased risk at level of >50233 234 mg/dL then >100 mg/dL were less consistent in the context of stroke wherein Lp(a) is associated with 235 stroke in ARIC but not MESA. Similar to MI in ARIC there was a stepwise increase in effect size at 236 higher Lp(a) levels, which was a lower effect size than that observed in MI. However, the associations in 237 MESA were absent. Prior studies testing the association between Lp(a) and stroke have been variable, 238 with one meta-analysis suggesting that the impact of Lp(a) on increased risk for stroke may be more likely among cohort <55 years old.²⁵ 239 240 Our study has important clinical implications in the context that both SDOH and LS7 were 241 consistent predictors of ASCVD. This consistency suggests that SDOH and lifestyle factors should 242 continue to be the focus of clinicians. Health systems should continue to increase screening for SDOH and create pathways for managing SDOH when they are identified.^{2,26,27} 243 244 There are also implications surrounding the observation that when SDOH and LS7 were added to 245 the model, these mediated the association of other covariates. The associations between non-Hispanic 246 Black or Hispanic participants and CVD events decreased or inverted as SDOH and LS7 were added to 247 the models. This suggests that non-Hispanic Black or Hispanic participants' SDOH and LS7 scores were 248 confounding associations as mediators between race and ethnicity with MI or stroke. Addressing SDOH 249 and lifestyle factors can therefore be seen as a chance for healthy equity in managing risk for ASCVD.^{2,26,28} Future studies looking at associations between race and ethnicity and events should 250 251 recognize our observations and that differences across race and ethnicity are driven by non-biologic factors (e.g., structural inequities).^{8,29,30} 252 253 Lastly, when SDOH and lifestyle factors were included in the models, the effect size for the 254 association between non-HDL-C and outcomes was reduced or eliminated. The largest shift occurred

when the LS7 score was added to the model. This suggests that some of the association between

atherogenic lipids and risk for ASCVD is driven by lifestyle factors. The LS7 score includes a lipid

257	component, thus there could be collinearity of variables in the model. Lastly, the effect size of non-HDL-
258	C on outcomes could have been reduced in the context that we were unable to track therapies introduced
259	over time. If those with higher non-HDL-C were more likely to be treated with lipid lowering therapies
260	then this could confound this association.
261	Strengths
262	A strength of this study is that we used two large cohorts with long follow up periods and many
263	of the observations were similar between cohorts. Additionally we used multiple methods and yielded
264	similar results, including matching cases of $Lp(a) \ge 50 \text{ mg/dL}$ to controls that were similar on many
265	factors.
266	Limitations
267	Our study has limitations. There may be additional SDOH that were not measured in either
268	cohort. Several of the items are self-reported, which could be subject to social desirability bias and
269	incomplete data collection. Lastly, these data are observational and further work needs to be done to
270	understand the mechanisms by which SDOH and lifestyle alter the biochemistry of Lp(a).
271	Conclusions
272	Our findings support that Lp(a) is an independent risk factor for cardiovascular events and that
273	this associated risk is not greatly impacted by SDOH or lifestyle factors. In addition, SDOH and lifestyle
274	factors are strong predictors of ASCVD risk that may explain some of the association between race and
275	ethnicity or non-HDL-C with MI or stroke. This impact of SDOH and LS7 should be considered when
276	designing and interpreting observational and clinical studies.

277 Acknowledgements: None

- 279 Sources of Funding: NIH K23MD017253
- 280
- 281 Disclosures: EJB reports research funding from the National Institutes of Health (K23MD017253) and the
- 282 Blue Cross Blue Shield of Michigan Foundation. He has received consulting fees from New Amsterdam
- 283 Pharmaceuticals. VLM is supported by the Melvyn Rubenfire Professorship in Preventive Cardiology. He
- serves as principal investigator for grants R01HL136685, R01AG05979, and U01DK123013 from the
- 285 National Institutes of Health. VLM owns stock in Amgen, Merck, Pfizer, and Eli Lilly. Other authors
- 286 (MK, BP, CC, SNG) have no disclosures to report.

287 References

288	1.	Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging
289		Therapies. J Am Coll Cardiol [Internet]. 2017;69:692–711. Available from:
290		http://dx.doi.org/10.1016/j.jacc.2016.11.042
291	2.	Brandt EJ, Tobb K, Cambron JC, Ferdinand K, Douglass P, Nguyen PK, Vijayaraghavan K, Islam S,
292		Thamman R, Rahman S, Pendyal A, Sareen N, Yong C, Palaniappan L, Ibebuogu U, Tran A,
293		Bacong AM, Lundberg G, Watson K. Assessing and Addressing Social Determinants of
294		Cardiovascular Health: JACC State-of-the-Art Review. J Am Coll Cardiol [Internet]. 2023;81:1368-
295		1385. Available from: http://dx.doi.org/10.1016/j.jacc.2023.01.042
296	3.	Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K,
297		Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA,
298		Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD, American Heart
299		Association Strategic Planning Task Force and Statistics Committee. Defining and setting national
300		goals for cardiovascular health promotion and disease reduction: the American Heart Association's
301		strategic Impact Goal through 2020 and beyond. Circulation [Internet]. 2010;121:586-613.
302		Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192703
303	4.	Perrot N, Verbeek R, Sandhu M, Boekholdt SM, Hovingh GK, Wareham NJ, Khaw KT, Arsenault
304		BJ. Ideal cardiovascular health influences cardiovascular disease risk associated with high
305		lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis
306		[Internet]. 2017;256:47-52. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2016.11.010
307	5.	Foscolou A, Georgousopoulou E, Magriplis E, Naumovski N, Rallidis L, Matalas AL, Chrysohoou
308		C, Tousoulis D, Pitsavos C, Panagiotakos D. The mediating role of Mediterranean diet on the
309		association between Lp(a) levels and cardiovascular disease risk: A 10-year follow-up of the

- 310 ATTICA study. *Clin Biochem* [Internet]. 2018;60:33–37. Available from:
- 311 http://dx.doi.org/10.1016/j.clinbiochem.2018.07.011
- 312 6. Satcher D. Include a social determinants of health approach to reduce health inequities. *Public*
- 313 *Health Rep* [Internet]. 2010;125 Suppl 4:6–7. Available from:
- 314 http://dx.doi.org/10.1177/00333549101250s402
- 315 7. Palacio A, Mansi R, Seo D, Suarez M, Garay S, Medina H, Tang F, Tamariz L. Social determinants
- 316 of health score: does it help identify those at higher cardiovascular risk? *Am J Manag Care*
- 317 [Internet]. 2020;26:e312–e318. Available from: http://dx.doi.org/10.37765/ajmc.2020.88504
- 8. Bundy JD, Mills KT, He H, LaVeist TA, Ferdinand KC, Chen J, He J. Social determinants of health
- and premature death among adults in the USA from 1999 to 2018: a national cohort study. *Lancet*
- 320 *Public Health* [Internet]. 2023;8:e422–e431. Available from: http://dx.doi.org/10.1016/S2468 321 2667(23)00081-6
- 322 9. Teshale AB, Htun HL, Owen A, Gasevic D, Phyo AZZ, Fancourt D, Ryan J, Steptoe A, Freak-Poli
- 323 R. The Role of Social Determinants of Health in Cardiovascular Diseases: An Umbrella Review. J
- 324 *Am Heart Assoc* [Internet]. 2023;12:e029765. Available from:
- 325 http://dx.doi.org/10.1161/JAHA.123.029765
- 326 10. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G,
- 327 Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, Rosal M, Yancy CW, American Heart
- 328 Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and
- 329 Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and
- 330 Cardiometabolic Health, and Stroke Council. Social Determinants of Risk and Outcomes for
- 331 Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*
- 332 [Internet]. 2015;132:873–898. Available from: http://dx.doi.org/10.1161/CIR.0000000000228

- 333 11. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins
- 334 [Internet]. MDText.com, Inc.; 2022 [cited 2023 Jul 11]. Available from:
- 335 https://www.ncbi.nlm.nih.gov/books/NBK326741/
- 12. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a].
- 337 Structural properties. *J Biol Chem* [Internet]. 1983;258:4582–4589. Available from:
- 338 https://www.ncbi.nlm.nih.gov/pubmed/6220008
- 339 13. Gaubatz JW, Cushing GL, Morrisett JD. Quantitation, isolation, and characterization of human
 340 lipoprotein (a). *Methods Enzymol.* 1986;129:167–186.
- 341 14. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH,
- 342 Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between
- 343 lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis
- Risk in Communities (ARIC) Study. *Circulation* [Internet]. 2012;125:241–249. Available from:
- 345 http://dx.doi.org/10.1161/circulationaha.111.045120
- 346 15. Agarwala A, Pokharel Y, Saeed A, Sun W, Virani SS, Nambi V, Ndumele C, Shahar E, Heiss G,
- 347 Boerwinkle E, Konety S, Hoogeveen RC, Ballantyne CM. The association of lipoprotein(a) with
- 348 incident heart failure hospitalization: Atherosclerosis Risk in Communities study. *Atherosclerosis*
- 349 [Internet]. 2017;262:131–137. Available from:
- 350 http://dx.doi.org/10.1016/j.atherosclerosis.2017.05.014
- 351 16. Guan W, Cao J, Steffen BT, Post WS, Stein JH, Tattersall MC, Kaufman JD, McConnell JP,
- 352 Hoefner DM, Warnick R, Tsai MY. Race is a key variable in assigning lipoprotein(a) cutoff values
- 353 for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. *Arterioscler*
- 354 *Thromb Vasc Biol* [Internet]. 2015;35:996–1001. Available from:
- 355 http://dx.doi.org/10.1161/atvbaha.114.304785

- 356 17. Rikhi R, Hammoud A, Ashburn N, Snavely AC, Michos ED, Chevli P, Tsai MY, Herrington D,
- 357 Shapiro MD. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular
- 358 risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis [Internet]. 2022;363:102–
- 359 108. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2022.10.004
- 360 18. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-
- 361 Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ,
- 362 O'Dea L, Witztum JL. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J
- 363 *Med* [Internet]. 2020;382:244–255. Available from:
- 364 https://www.nejm.org/doi/full/10.1056/NEJMoa1905239
- 365 19. Jamialahmadi T, Reiner Ž, Alidadi M, Kroh M, Almahmeed W, Ruscica M, Sirtori C, Rizzo M,
- 366 Santos RD, Sahebkar A. The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A
- 367 Meta-analysis. *Biomed Res Int* [Internet]. 2022;2022:8435133. Available from:
- 368 http://dx.doi.org/10.1155/2022/8435133
- 369 20. Hoursalas A, Tsarouhas K, Tsitsimpikou C, Kolovou G, Vardavas A, Hoursalas I, Spandidos DA,
- 370 Milionis H, Elisaf M, Tsiara S. Moderately elevated lipoprotein (a) levels are associated with an
- arlier need for percutaneous coronary intervention in recurrent cardiovascular disease. *Exp Ther*
- 372 *Med* [Internet]. 2022;24:444. Available from: http://dx.doi.org/10.3892/etm.2022.11371
- 21. Corsetti JP, Sterry JA, Sparks JD, Sparks CE, Weintraub M. Effect of weight loss on serum
 374 lipoprotein(a) concentrations in an obese population. *Clin Chem* [Internet]. 1991;37:1191–1195.
- 375 Available from: https://www.ncbi.nlm.nih.gov/pubmed/1830250
- 22. Berk KA, Yahya R, Verhoeven AJM, Touw J, Leijten FP, van Rossum EF, Wester VL, Lips MA,
- 377 Pijl H, Timman R, Erhart G, Kronenberg F, Roeters van Lennep JE, Sijbrands EJG, Mulder MT.
- 378 Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type

379 2 diabetes. *Diabetologia* [Internet]. 2017;60:989–997. Available from:

- 380 http://dx.doi.org/10.1007/s00125-017-4246-y
- 381 23. Kim S, Chang Y, Cho J, Hong YS, Zhao D, Kang J, Jung H-S, Yun KE, Guallar E, Ryu S, Shin H.
- 382 Life's Simple 7 Cardiovascular Health Metrics and Progression of Coronary Artery Calcium in a
- 383 Low-Risk Population. *Arterioscler Thromb Vasc Biol* [Internet]. 2019;39:826–833. Available from:
- 384 http://dx.doi.org/10.1161/ATVBAHA.118.311821
- 385 24. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins
- 386 R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease,
- 387 stroke, and nonvascular mortality. *JAMA* [Internet]. 2009;302:412–423. Available from:
- 388 http://dx.doi.org/10.1001/jama.2009.1063
- 389 25. Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, Steinhagen-Thiessen
- 390 E, Endres M, Ebinger M. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis.
- 391 *Atherosclerosis* [Internet]. 2015;242:496–503. Available from:
- 392 http://dx.doi.org/10.1016/j.atherosclerosis.2015.08.021
- 393 26. Velarde G, Bravo-Jaimes K, Brandt EJ, Wang D, Douglass P, Castellanos LR, Rodriguez F,
- Palaniappan L, Ibebuogu U, Bond R, Ferdinand K, Lundberg G, Thaman R, Vijayaraghavan K,
- 395 Watson K. Locking the Revolving Door: Racial Disparities in Cardiovascular Disease. J Am Heart

396 *Assoc* [Internet]. 2023;e025271. Available from: http://dx.doi.org/10.1161/JAHA.122.025271

- 397 27. Vanjani R, Reddy N, Giron N, Bai E, Martino S, Smith M, Harrington-Steppen S, Trimbur MC. The
- 398 Social Determinants of Health Moving Beyond Screen-and-Refer to Intervention. N Engl J Med
- 399 [Internet]. 2023;389:569–573. Available from: https://doi.org/10.1056/NEJMms2211450
- 400 28. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD,
- 401 Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani

402	SS,	Williams KA Sr	, Yeboah J	, Ziaeian B	. 2019 ACC/AHA	Guideline or	n the Primary	y Prevention o

- 403 Cardiovascular Disease: Executive Summary: A Report of the American College of
- 404 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll
- 405 *Cardiol* [Internet]. 2019;140:e563–e595. Available from:
- 406 http://dx.doi.org/10.1016/j.jacc.2019.03.009
- 407 29. Braveman P, Parker Dominguez T. Abandon "Race." Focus on Racism. Front Public Health
- 408 [Internet]. 2021;9:689462. Available from: http://dx.doi.org/10.3389/fpubh.2021.689462
- 409 30. Javed Z, Haisum Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, Andrieni J, Dubey P,
- 410 Jackson RK, Daffin MA, Cainzos-Achirica M, Hyder AA, Nasir K. Race, Racism, and
- 411 Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic
- 412 Disparities in Cardiovascular Disease. *Circ Cardiovasc Qual Outcomes* [Internet]. 2022;15:e007917.
- 413 Available from: http://dx.doi.org/10.1161/CIRCOUTCOMES.121.007917
- 414 Figure Legends
- 415
- 416 Figure 1: Cox proportional hazards regression results for association of $Lp(a) \ge 50 \text{ mg/dL}$ or < 50 mg/dL or <
- 417 mg/dL with myocardial infarction or stroke in ARIC and MESA^a
- 418
- 419 ^a These proportional hazards regression graphs were generated after exposures ($Lp(a) \ge 50$
- 420 mg/dL) were matched using coarsened exact matching to controls (Lp(a) ≤ 50 mg/dL). Covariates
- 421 included age, gender, race and ethnicity, non-HDL-C, SDOH score, and LS7 score.

rable 1. ropulation characteristics	(1, 15, 027) 101 AKIC, 11, 0, 022 101 WILSP	1)
	ARIC	MESA
	n, % or mean (SD)	n, % or mean (SD)
Age (years)	54 (6)	62 (10)
Female	8196, 54.5%	3601, 52.9%
Race and Ethnicity	-	-
Non-Hispanic White	11,110, 73.9%	2,622, 38.5%
Non-Hispanic Black	3917, 26.1%	1892, 27.8%
Non-Hispanic Chinese	n/a	804, 11.8%
Hispanic	n/a	1496, 22.0%
Lipoprotein(a) (mg/dL)	30.3 (32.1)	30.1 (34.0)
Non-HDL-C (mg/dL)	155 (43.9)	134 (36.1)
SDOH Score	1.0 (1.1)	2.3 (1.7)
Life's Simple 7 Score	7.8 (2.3)	8.3 (2.1)

422 Table 1: Population characteristics (n=15,027 for ARIC, n=6,822 for MESA)

Abbreviations: ARIC = Atherosclerosis Risk in Communities; MESA=Multi-Ethnic Study of Atherosclerosis; Non-

424 HDL-C = Non-High Density Lipoprotein-Cholesterol; SDOH = Social Determinants of Health

425 426 427 428 Table 2: Sequential Multivariable Cox Proportional Hazards Regression for Myocardial Infarction in ARIC and

MESA

A: ARIC (n=14,306)

		Model 1			Model 2			Model 3	
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.09	1.09, 1.10	< 0.001	1.09	1.08, 1.10	< 0.001	1.09	1.08, 1.10	< 0.001
Male	1.62	1.52, 1.74	< 0.001	1.62	1.52, 1.73	< 0.001	1.60	1.50, 1.71	< 0.001
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.34	1.24, 1.45	< 0.001	1.13	1.04, 1.23	0.006	0.88	0.80, 0.96	0.003
Non-HDL-C (per 25 mg/dL increase)	1.16	1.14, 1.18	< 0.001	1.15	1.13, 1.17	< 0.001	1.04	1.02, 1.06	< 0.001
Lipoprotein(a) (per 25 mg/dL increase)	1.11	1.08, 1.14	< 0.001	1.11	1.08, 1.14	< 0.001	1.09	1.06, 1.12	< 0.001
SDOH Score (per 1 point increase)	-	-	-	1.22	1.18, 1.26	< 0.001	1.13	1.09, 1.17	< 0.001
Life's Simple 7 Score (per 1 point increase)	-	-	-	-	-	-	0.81	0.80, 0.83	< 0.001

429 430

B: MESA (n=6,668)

	Model 1			Model 2			Model 3	
HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
1.06	1.05. 1.07	< 0.001	1.05	1.04, 1.06	< 0.001	1.05	1.04, 1.06	< 0.001
2.19	1.85, 2.58	< 0.001	2.36	2.00, 2.79	< 0.001	2.37	2.00, 2.80	< 0.001
-	-	-	-	-	-	-	-	-
Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
0.95	0.78, 1.17	0.65	0.86	0.70, 1.06	0.16	0.72	0.58, 0.89	0.002
0.78	0.59, 1.03	0.08	0.69	0.52, 0.92	0.01	0.78	0.58. 1.03	0.08
1.01	0.82, 1.24	0.92	0.81	0.65, 1.02	0.07	0.75	0.59, 0.94	0.012
1.09	1.03, 1.15	0.002	1.09	1.03, 1.15	0.003	1.02	0.96, 1.08	0.53
1.11	1.05, 1.17	< 0.001	1.11	1.05, 1.17	< 0.001	1.10	1.04, 1.16	0.001
-	-	-	1.14	1.08, 1.20	< 0.001	1.11	1.05, 1.17	< 0.001
-	-	-	-	-	-	0.84	0.81, 0.88	< 0.001
	1.06 2.19 - Ref 0.95 0.78 1.01 1.09	HR 95% CI 1.06 1.05. 1.07 2.19 1.85, 2.58 - - Ref Ref 0.95 0.78, 1.17 0.78 0.59, 1.03 1.01 0.82, 1.24 1.09 1.03, 1.15	HR 95% CI p-value 1.06 1.05. 1.07 <0.001	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

432 433 434 Table 3: Sequential Multivariable Cox Proportional Hazards Regression for Stroke in ARIC and MESA

A: ARIC (n=14,286)

A. ARIC (II 17,200)									
		Model 1			Model 2			Model 3	
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.11	1.10, 1.12	< 0.001	1.11	1.10, 1.12	< 0.001	1.11	1.10, 1.12	< 0.001
Male	1.28	1.16, 1.40	< 0.001	1.27	1.15, 1.39	< 0.001	1.25	1.14, 1.38	< 0.001
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.96	1.77, 2.18	< 0.001	1.60	1.43, 1.80	< 0.001	1.24	1.10, 1.40	< 0.001
Non-HDL-C (per 25	1.09	1.06, 1.11	< 0.001	1.08	1.05, 1.11	< 0.001	0.98	0.95, 1.01	0.13
mg/dL increase)									
Lipoprotein(a) (per 25	1.08	1.05, 1.12	< 0.001	1.08	1.04, 1.12	< 0.001	1.06	1.02, 1.09	0.003
mg/dL increase)									
SDOH Score (per 1	-	-	-	1.26	1.20, 1.31	< 0.001	1.17	1.12, 1.22	< 0.001
point increase)									
Life's Simple 7 Score	-	-	-	-	-	-	0.82	0.80, 0.84	< 0.001
(per 1 point increase)									

435 436

B: MESA (n=6,666)

D. WILSA (II 0,000)									
		Model 1			Model 2			Model 3	
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.07	1.06, 1.09	< 0.001	1.07	1.06, 1.08	< 0.001	1.07	1.06, 1.08	< 0.001
Male	1.26	1.00, 1.59	0.05	1.34	1.05, 1.70	0.02	1.34	1.05, 1.70	0.02
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.43	1.06, 1.95	0.02	1.34	0.99, 1.83	0.06	1.12	0.82, 1.54	0.47
Non-Hispanic	0.64	0.40, 1.04	0.07	0.59	0.36, 0.96	0.03	0.66	0.41, 1.08	0.10
Chinese									
Hispanic	1.53	1.14, 2.06	0.005	1.31	0.95, 1.82	0.10	1.20	0.87, 1.66	0.27
Non-HDL-C (per 25	1.10	1.01, 1.19	0.02	1.10	1.01, 1.19	0.03	1.03	0.94, 1.12	0.54
mg/dL increase)									
Lipoprotein(a) (per 25	0.97	0.89, 1.07	0.58	0.97	0.88, 1.07	0.56	0.96	0.87, 1.05	0.39
mg/dL increase)									
SDOH Score (per 1	-	-	-	1.10	1.02, 1.19	0.02	1.07	0.99, 1.15	0.11
point increase)									
Life's Simple 7 Score	-	-	-	-	-	-	0.84	0.79, 0.89	< 0.001
(per 1 point increase)									

438 Table 4: Population Characteristics Cases with Lipoprotein(a) \geq 50 mg/dL and Controls with Lipoprotein(a) < 50

439 mg/dL after Coarsened Exact Matching Weights Applied

440 441

A: ARIC Controls Cases p-value n, % or mean (SD) n, % or mean (SD) Age (years) 54.3 (5.8) 54.3 (5.8) 0.66 Female 6826, 60.9% 1872, 60.9% 1.00Race and Ethnicity -Non-Hispanic White 6224, 44.5% 1366, 44.5% 1.00 Non-Hispanic Black 4981, 55.6% 1366, 55.6% 1.00 Lipoprotein(a) (mg/dL) 19.4 (13.9) 81.3 (30.1) < 0.001Non-HDL-C (mg/dL) 150 (45.0) 149 (44.4) 0.73 SDOH Score 1.2 (1.2) 1.2 (1.1) 0.80 Life's Simple 7 Score 7.5 (2.3) 7.4 (2.3) 0.07

442

443 B: MESA

	Controls	Cases	p-value
	n, % or mean (SD)	n, % or mean (SD)	1
Age (years)	62.3 (9.9)	62.3 (10.0)	0.83
Female	2554, 5.87%	773, 58.7%	1.00
Race and Ethnicity	-	-	-
Non-Hispanic White	1364, 31.4%	413, 31.4%	1.00
Non-Hispanic Black	2051, 47.2%	621, 47.2%	1.00
Non-Hispanic Chinese	248, 5.7%	75, 5.7%	1.00
Hispanic	683, 15.7%	207, 15.7%	1.00
Lipoprotein(a) (mg/dL)	18.8 (13.3)	86.0 (34.6)	< 0.001
Non-HDL-C (mg/dL)	125.8 (33.3)	122.7 (35.3)	0.005
SDOH Score	2.3 (1.7)	2.3 (1.7)	0.78
Life's Simple 7 Score	8.2 (2.0)	8.1 (2.0)	0.38

445 Table 5: Sequential Multivariable Cox Proportional Hazards Regression for Myocardial Infarction in ARIC and

MESA After Coarsened Exact Matching

446 447

448 A: ARIC (n=14,010)

		Model 1			Model 2			Model 3	
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.10	1.09, 1.10	< 0.001	1.09	1.09, 1.10	< 0.001	1.09	1.09, 1.10	< 0.001
Male	1.54	1.44, 1.64	< 0.001	1.53	1.43, 1.64	< 0.001	1.57	1.46, 1.68	< 0.001
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.39	1.30, 1.49	< 0.001	1.17	1.09, 1.26	< 0.001	0.89	0.82, 0.96	0.003
Non-HDL-C (per 25	1.15	1.13, 1.17	< 0.001	1.14	1.12, 1.16	< 0.001	1.03	1.01, 1.05	0.01
mg/dL increase)									
Lipoprotein(a)	-	-	-	-	-	-	-	-	-
0 to <50 mg/dL	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
≥50 to <100 mg/dL	1.15	0.001	0.001	1.16	1.07, 1.27	0.001	1.13	1.04, 1.23	0.005
<u>≥</u> 100 mg/dL	1.53	< 0.001	< 0.001	1.53	1.33, 1.77	< 0.001	1.44	1.24, 1.66	< 0.001
SDOH Score (per 1	-	-		1.20	1.16, 1.24	< 0.001	1.12	1.08, 1.15	< 0.001
point increase)									
Life's Simple 7 Score	-	-		-	-		0.81	0.79, 0.82	< 0.001
(per 1 point increase)									

449 450

B: MESA (n=5,573)

D. MILDIA (II $(3,373)$									
	Model 1			Model 2			Model 3		
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.05	1.04. 1.06	< 0.001	1.05	1.04, 1.06	< 0.001	1.04	1.03, 1.05	< 0.001
Male	2.06	1.72, 2.46	< 0.001	2.24	1.86, 2.68	< 0.001	2.21	1.84, 2.65	< 0.001
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.00	0.82, 1.22	0.98	0.90	0.73, 1.11	0.32	0.77	0.62, 0.95	0.02
Non-Hispanic	0.63	0.39, 1.01	0.06	0.55	0.34, 0.90	0.02	0.63	0.38. 1.02	0.06
Chinese									
Hispanic	0.95	0.72, 1.25	0.70	0.72	0.53, 0.97	0.03	0.68	0.50, 0.92	0.01
Non-HDL-C (per 25	1.05	0.98, 1.12	0.18	1.05	0.98, 1.12	0.18	0.99	0.93, 1.07	0.88
mg/dL increase)									
Lipoprotein(a)	-	-	-	-	-	-	-	-	-
0 to <50 mg/dL	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
≥50 to <100 mg/dL	1.21	0.97, 1.52	0.09	1.23	0.98, 1.53	0.07	1.20	0.96, 1.50	0.12
≥100 mg/dL	1.60	1.15, 2.22	0.005	1.60	1.15, 2.23	0.005	1.57	1.13, 2.19	0.007
SDOH Score (per 1	-	-	-	1.16	1.09, 1.22	< 0.001	1.13	1.05, 1.17	< 0.001
point increase)									
Life's Simple 7 Score	-	-	-	-	-	-	0.86	0.81, 0.88	< 0.001
(per 1 point increase)									

453 Table 6: Sequential Multivariable Cox Proportional Hazards Regression for Stroke in ARIC and MESA After

454 455 Coarsened Exact Matching

456 A: ARIC (n=13,989)

	Model 1			Model 2			Model 3		
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.10	1.09,1.11	< 0.001	1.10	1.09, 1.10	< 0.001	1.10	1.09, 1.10	< 0.001
Male	1.27	1.16, 1.40	< 0.001	1.25	1.14, 1.37	< 0.001	1.27	1.16, 1.40	< 0.001
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.99	1.81, 2.18	< 0.001	1.58	1.42, 1.74	< 0.001	1.18	1.06, 1.31	0.003
Non-HDL-C (per 25	1.04	1.02, 1.07	0.001	1.03	1.01, 1.06	0.02	0.93	0.90, 0.96	< 0.001
mg/dL increase)									
Lipoprotein(a)	-	-	-	-	-	-	-	-	-
0 to <50 mg/dL	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
≥50 to <100 mg/dL	1.18	1.05, 1.33	0.006	1.19	1.06, 1.34	0.004	1.17	1.04, 1.31	0.01
≥100 mg/dL	1.35	1.10, 1.64	0.003	1.33	1.09, 1.62	0.005	1.26	1.03, 1.53	0.02
SDOH Score (per 1	-	-	-	1.26	1.21, 1.31	< 0.001	1.18	1.13, 1.23	< 0.001
point increase)									
Life's Simple 7 Score	-	-	-	-	-	-	0.81	0.79, 0.83	< 0.001
(per 1 point increase)									


457

458 B: MESA (n=5.575)

D. MESA $(II = 3, 373)$	-			-			-		
	Model 1			Model 2			Model 3		
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (per year)	1.07	1.06, 1.09	< 0.001	1.07	1.05, 1.08	< 0.001	1.07	1.05, 1.08	< 0.001
Male	1.26	0.97, 1.64	0.08	1.34	1.03, 1.76	0.03	1.33	1.01, 1.74	0.04
Race and Ethnicity	-	-	-	-	-	-	-	-	-
Non-Hispanic White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Non-Hispanic Black	1.24	0.91, 1.69	0.17	1.15	0.84, 1.58	0.37	0.97	0.70, 1.34	0.51
Non-Hispanic	0.76	0.37, 1.53	0.44	0.69	0.34, 1.40	0.30	0.79	0.39, 1.61	0.87
Chinese									
Hispanic	1.52	1.04, 2.23	0.03	1.23	0.81, 1.88	0.33	1.15	0.75, 1.76	0.51
Non-HDL-C (per 25	1.09	0.98, 1.20	0.08	1.09	0.99, 1.20	0.08	1.03	0.93, 1.14	0.55
mg/dL increase)									
SDOH Score (per 1	-	-	-	1.11	1.02, 1.22	0.02	1.08	0.99, 1.15	0.08
point increase)									
Life's Simple 7 Score	-	-	-	-	-	-	0.84	0.79, 0.89	< 0.001
(per 1 point increase)									

459

- 461 Figure 1: Cox proportional hazards regression results for association of $Lp(a) \ge 50 \text{ mg/dL}$ or < 50 mg/dL
- 462 with myocardial infarction or stroke in ARIC and MESA
- 463 A: Event free survival in ARIC by Lp(a) level



464 465

466

Lp(a)<50 mg/dL

Lp(a)>=100 mg/dL

Lp(a)>=50 to 100 mg/dL

Lp(a)<50 mg/dL

Lp(a)>=100 mg/dL

Lp(a)>=50 to 100 mg/dL